Michael Contarino
Papers
1
Total Citations
4
H-Index
1
About
Michael Contarino’s research has centered on advancing drug development through innovative ADME/Tox screening technologies. His most cited work, "ADMET Assays on Tecan's LabCD-ADMET System" (2003), introduced a microfluidic platform for evaluating critical drug properties—Cytochrome P450 inhibition, serum protein binding, and P-glycoprotein interaction. This contribution streamlined early-stage pharmacokinetic profiling, enabling faster identification of promising drug candidates. Though his citation count is modest, Contarino’s impact lies in pioneering lab-on-a-chip methodologies that reduced reagent consumption and assay time, influencing subsequent high-throughput screening designs. His work at the intersection of microfluidics and pharmacology remains a practical reference for researchers developing automated ADMET systems. By demonstrating the LabCD’s reliability for these three key assays, Contarino helped bridge the gap between academic innovation and industrial drug discovery workflows.
Research Focus
Key Achievements
Top Papers
- 1ADMET Assays on Tecan's LabCD-ADMET System4 citations · 2003